Stox
20
Mangalam Drugs And Organics Limited
NSE: MANGALAM · Unclassified
₹28.80-6.01%06 Nov 2026
Ask the data
Instant answers about Mangalam Drugs And Organics Limited — computed from its filings, no language modelMarket cap₹46 cr
Current price₹28.80
High / Low₹67 / ₹24
P/E—
P/B0.52
Book value₹55.6
ROE-11.2%
ROCE-13.7%
Debt / equity1.00
Dividend yield—
EPS (TTM)₹-6.22
Face value₹10
Price & valuation
split & bonus adjusted · pick a metric and rangeAnnual performance
annual · ₹ crore · line = operating margin| FY24 | FY26 | |
|---|---|---|
| Revenue | 368.6 | 232.1 |
| EBITDA | 17.4 | -14.9 |
| Operating margin | 4.7% | -6.4% |
| Interest | 13.9 | 16.2 |
| Depreciation | 14.7 | 18.2 |
| Profit before tax | -11.1 | -48.6 |
| Tax | -2.0 | -4.2 |
| Net profit | 0.0 | 0.0 |
| EPS ₹ | -5.73 | -28.05 |
| Operating cash flow | -11.1 | 4.2 |
| Capex | 0.0 | 11.9 |
| Dividend paid | 0.0 | 0.0 |
| Total assets | 333.4 | 315.0 |
| Equity | 135.8 | 103.1 |
Quarterly performance
last 11 quarters · ₹ crore| SEP '23 | DEC '23 | MAR '24 | JUN '24 | SEP '24 | DEC '24 | SEP '25 | DEC '25 | MAR '26 | JUN '26 | SEP '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.0 | 97.3 | 102.2 | 76.5 | 79.9 | 88.7 | 49.5 | 58.5 | 67.3 | 57.1 | 79.4 |
| Operating profit | 0.0 | 7.0 | 11.7 | 8.2 | 8.7 | 8.8 | -2.8 | -1.4 | -5.6 | 0.9 | -1.1 |
| Operating margin | — | 7.2% | 11.4% | 10.7% | 10.9% | 9.9% | -5.7% | -2.4% | -8.4% | 1.6% | -1.4% |
| Other income | 0.0 | 0.0 | 0.1 | 0.0 | 0.1 | 0.1 | 0.0 | 0.1 | 0.1 | 0.1 | 0.2 |
| Interest | 0.0 | 3.3 | 4.0 | 3.8 | 3.7 | 3.5 | 5.0 | 4.0 | 3.1 | 3.7 | 3.9 |
| Depreciation | 0.0 | 3.6 | 3.9 | 3.9 | 4.0 | 4.0 | 4.6 | 4.5 | 4.7 | 4.1 | 4.1 |
| Profit before tax | 0.0 | 0.0 | 3.9 | 0.6 | 1.2 | 1.4 | -12.5 | -9.8 | -13.3 | -6.8 | -9.0 |
| Tax | 0.0 | -0.5 | 0.4 | -2.1 | -1.5 | 0.1 | -5.1 | 0.0 | 0.1 | 0.9 | -1.8 |
| Net profit | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -9.8 | 0.0 | 0.0 | 0.0 |
| EPS ₹ | 0.00 | 0.31 | 2.23 | 1.70 | 1.70 | 0.81 | -4.64 | -6.21 | -8.48 | -4.83 | -4.55 |
| Revenue YoY | — | — | — | — | — | -8.9% | -38.0% | -34.1% | — | — | 60.3% |
Earlier results (standalone, Sep '07 – Jun '23)
₹ crore · from BSE, before the NSE XBRL filings beginMangalam Drugs And Organics Limited reports consolidated figures above. Quarterly consolidated results only became mandatory in India in 2019, so the earlier history available is the standalone company only (excluding subsidiaries). It is shown separately so the two bases are never mixed.
Full years
| FY09† | FY10† | FY11† | FY12† | FY13† | FY14† | FY15† | FY16† | FY17† | FY18† | FY19† | FY20† | FY21† | FY22† | FY23† | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 102.4 | 112.3 | 131.3 | 152.2 | 126.3 | 122.7 | 220.7 | 295.2 | 311.7 | 283.9 | 227.6 | 282.3 | 380.1 | 433.8 | 372.3 |
| Operating profit | 8.8 | 10.4 | 12.6 | 14.6 | -3.4 | 9.8 | 20.4 | 37.7 | 48.4 | 46.9 | 9.7 | 23.7 | 53.3 | 31.8 | 25.5 |
| Operating margin | 8.6% | 9.3% | 9.6% | 9.6% | -2.7% | 8.0% | 9.2% | 12.8% | 15.5% | 16.5% | 4.3% | 8.4% | 14.0% | 7.3% | 6.9% |
| Other income | 0.4 | 0.5 | 0.6 | 0.4 | 0.5 | — | — | 0.0 | 0.1 | 0.8 | 0.3 | 1.2 | 4.7 | — | 0.4 |
| Interest | 5.1 | 5.7 | 6.9 | 10.2 | 10.0 | 9.7 | 10.3 | 9.3 | 10.0 | 11.8 | 8.7 | 10.4 | 9.3 | 11.2 | 12.8 |
| Depreciation | 2.6 | 3.0 | 3.3 | 3.7 | 3.9 | 4.0 | 4.2 | 4.4 | 5.0 | 6.6 | 7.1 | 8.2 | 9.2 | 10.2 | 11.0 |
| Profit before tax | 1.5 | 2.2 | 3.0 | 1.1 | -16.8 | -3.9 | 6.0 | 24.0 | 33.4 | 29.4 | -5.7 | 6.2 | 39.5 | 27.7 | 2.2 |
| Tax | 0.7 | 0.9 | 0.9 | 0.5 | -5.0 | -0.9 | -0.1 | 8.0 | 9.7 | 9.4 | 2.3 | -2.0 | 11.6 | 8.1 | 0.9 |
| Net profit | 0.8 | 1.3 | 2.1 | 0.6 | -11.8 | -3.0 | 6.1 | 16.0 | 23.7 | 19.9 | -8.0 | 8.2 | 28.0 | 19.7 | 1.3 |
Quarters
| SEP '07† | DEC '07† | MAR '08† | JUN '08† | SEP '08† | DEC '08† | MAR '09† | JUN '09† | SEP '09† | DEC '09† | MAR '10† | JUN '10† | SEP '10† | DEC '10† | MAR '11† | JUN '11† | SEP '11† | DEC '11† | MAR '12† | JUN '12† | SEP '12† | DEC '12† | MAR '13† | JUN '13† | SEP '13† | DEC '13† | MAR '14† | JUN '14† | SEP '14† | DEC '14† | MAR '15† | JUN '15† | SEP '15† | DEC '15† | MAR '16† | JUN '16† | SEP '16† | DEC '16† | MAR '17† | JUN '17† | SEP '17† | DEC '17† | MAR '18† | JUN '18† | SEP '18† | DEC '18† | MAR '19† | JUN '19† | SEP '19† | DEC '19† | MAR '20† | JUN '20† | SEP '20† | DEC '20† | MAR '21† | JUN '21† | SEP '21† | DEC '21† | MAR '22† | JUN '22† | SEP '22† | DEC '22† | MAR '23† | JUN '23† | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 24.7 | 21.0 | 27.8 | 22.9 | 25.7 | 26.9 | 26.9 | 27.5 | 28.1 | 30.3 | 26.4 | 31.2 | 33.0 | 34.5 | 32.6 | 35.2 | 38.7 | 37.8 | 40.6 | 24.3 | 20.4 | 35.5 | 46.2 | 18.4 | 28.2 | 38.1 | 37.9 | 38.6 | 43.5 | 63.0 | 75.6 | 69.6 | 72.6 | 82.3 | 70.7 | 67.0 | 76.5 | 80.6 | 87.6 | 59.7 | 83.1 | 73.9 | 67.2 | 59.0 | 71.9 | 48.6 | 48.1 | 65.0 | 67.3 | 61.9 | 88.1 | 103.6 | 97.0 | 88.7 | 90.8 | 104.8 | 114.2 | 93.8 | 121.0 | 109.5 | 108.3 | 63.3 | 91.1 | 87.5 |
| Operating profit | 1.2 | 1.6 | 1.8 | 1.7 | 2.2 | 2.4 | 2.5 | 2.4 | 3.0 | 2.8 | 2.3 | 2.9 | 3.1 | 3.4 | 3.1 | 4.1 | 5.1 | 3.8 | 1.6 | -2.7 | -0.8 | 1.2 | -1.0 | -2.6 | 2.5 | 3.8 | 6.1 | 3.6 | 5.8 | 5.0 | 6.0 | 6.5 | 8.0 | 8.9 | 14.3 | 10.3 | 11.7 | 12.2 | 14.1 | 9.9 | 14.9 | 12.6 | 9.5 | 4.9 | 5.5 | -1.0 | 0.3 | 5.5 | 6.1 | 5.0 | 7.2 | 13.6 | 17.6 | 12.6 | 9.5 | 10.3 | 4.9 | 6.3 | 10.2 | 10.4 | 8.4 | 6.5 | 0.2 | -3.5 |
| Operating margin | 4.9% | 7.7% | 6.4% | 7.5% | 8.5% | 9.0% | 9.4% | 8.6% | 10.5% | 9.3% | 8.7% | 9.4% | 9.3% | 9.9% | 9.6% | 11.6% | 13.1% | 10.1% | 4.0% | -11.3% | -3.9% | 3.3% | -2.2% | -14.3% | 8.9% | 9.9% | 16.1% | 9.2% | 13.3% | 7.9% | 8.0% | 9.3% | 11.0% | 10.8% | 20.3% | 15.4% | 15.3% | 15.1% | 16.1% | 16.5% | 17.9% | 17.1% | 14.2% | 8.2% | 7.7% | -2.0% | 0.5% | 8.4% | 9.1% | 8.0% | 8.1% | 13.1% | 18.2% | 14.2% | 10.4% | 9.9% | 4.3% | 6.7% | 8.4% | 9.5% | 7.8% | 10.2% | 0.3% | -4.0% |
| Other income | 0.1 | 0.0 | 0.2 | 0.0 | 0.0 | 0.0 | 0.3 | 0.1 | 0.0 | 0.1 | 0.3 | 0.0 | 0.1 | 0.0 | 0.5 | 0.0 | 0.1 | 0.0 | 0.3 | 0.0 | 0.0 | 0.0 | 0.5 | 0.0 | — | 0.0 | 0.0 | 0.0 | 0.0 | — | 0.0 | 0.7 | 0.0 | 0.0 | -0.7 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.6 | 0.1 | 0.0 | 0.0 | 0.0 | 0.2 | 0.0 | 0.0 | 0.7 | 0.5 | 0.7 | 0.7 | 1.3 | 2.1 | 0.5 | 8.8 | 8.0 | — | 0.0 | 0.0 | 0.1 | 0.3 | 0.0 |
| Interest | 0.5 | 0.9 | 1.0 | 0.9 | 1.3 | 1.4 | 1.6 | 1.4 | 1.6 | 1.5 | 1.2 | 1.5 | 1.6 | 1.9 | 1.9 | 2.1 | 2.4 | 2.7 | 3.0 | 2.4 | 2.4 | 2.7 | 2.5 | 2.3 | 2.5 | 2.9 | 2.1 | 2.7 | 2.7 | 2.7 | 2.1 | 2.3 | 2.2 | 2.0 | 2.8 | 2.3 | 2.4 | 2.3 | 3.1 | 2.5 | 3.4 | 2.5 | 3.4 | 2.1 | 1.7 | 2.3 | 2.5 | 2.6 | 2.8 | 2.5 | 2.5 | 2.2 | 2.6 | 2.4 | 2.2 | 3.0 | 3.0 | 2.7 | 2.5 | 3.5 | 2.6 | 3.2 | 3.4 | 3.4 |
| Depreciation | 0.6 | 0.6 | 0.6 | 0.6 | 0.7 | 0.7 | 0.7 | 0.7 | 0.7 | 0.7 | 0.9 | 0.8 | 0.7 | 0.9 | 0.9 | 0.8 | 1.0 | 0.9 | 1.0 | 0.9 | 1.0 | 1.0 | 1.0 | 1.0 | 1.0 | 1.0 | 1.0 | 1.1 | 0.9 | 1.0 | 1.1 | 1.1 | 1.1 | 1.1 | 1.1 | 1.0 | 1.2 | 1.3 | 1.6 | 1.2 | 1.3 | 1.5 | 2.6 | 1.8 | 1.8 | 1.8 | 1.7 | 1.8 | 2.3 | 2.1 | 2.1 | 2.1 | 2.3 | 2.3 | 2.5 | 2.4 | 2.5 | 2.7 | 2.7 | 2.6 | 2.8 | 2.9 | 2.8 | 3.4 |
| Profit before tax | 0.2 | 0.1 | 0.4 | 0.3 | 0.3 | 0.4 | 0.6 | 0.4 | 0.7 | 0.6 | 0.5 | 0.7 | 0.8 | 0.7 | 0.8 | 1.2 | 1.8 | 0.2 | -2.1 | -6.0 | -4.2 | -2.5 | -4.0 | -5.9 | -1.0 | -0.1 | 3.0 | -0.2 | 2.2 | 1.3 | 2.8 | 3.8 | 4.7 | 5.8 | 9.8 | 7.0 | 8.2 | 8.7 | 9.5 | 6.2 | 10.3 | 9.3 | 3.6 | 1.0 | 2.0 | -5.1 | -3.7 | 1.0 | 1.1 | 1.0 | 3.0 | 10.1 | 13.4 | 9.2 | 6.8 | 5.5 | 8.3 | 8.9 | 5.0 | 4.2 | 3.1 | 0.5 | -5.7 | -10.3 |
| Tax | 0.1 | 0.0 | 0.3 | 0.1 | 0.1 | 0.1 | 0.5 | 0.1 | 0.2 | 0.2 | 0.3 | 0.2 | 0.2 | 0.2 | 0.3 | 0.4 | 0.2 | 0.0 | -0.2 | 0.0 | 0.0 | 0.0 | -5.0 | 0.0 | 0.0 | 0.0 | -0.9 | 0.0 | 0.1 | 0.5 | -0.7 | 0.7 | 1.1 | 2.0 | 4.2 | 1.9 | 2.4 | 2.5 | 2.9 | 2.0 | 3.6 | 3.3 | 0.6 | 0.4 | 0.3 | -0.7 | 2.3 | 0.3 | 0.3 | -0.6 | -2.0 | 1.8 | 2.4 | 2.8 | 4.7 | 1.1 | 3.8 | 4.9 | -1.7 | 1.2 | 0.9 | 0.1 | -1.3 | -0.8 |
| Net profit | 0.2 | 0.1 | 0.1 | 0.2 | 0.2 | 0.3 | 0.1 | 0.3 | 0.5 | 0.4 | 0.1 | 0.5 | 0.6 | 0.5 | 0.6 | 0.8 | 1.5 | 0.2 | -1.9 | -6.0 | -4.2 | -2.5 | 1.0 | -5.9 | -1.0 | -0.1 | 3.9 | -0.2 | 2.0 | 0.8 | 3.5 | 3.0 | 3.6 | 3.8 | 5.5 | 5.1 | 5.8 | 6.2 | 6.6 | 4.2 | 6.7 | 6.0 | 3.1 | 0.7 | 1.7 | -4.4 | -6.0 | 0.7 | 0.8 | 1.6 | 5.0 | 8.3 | 11.1 | 6.4 | 2.1 | 4.4 | 4.5 | 4.0 | 6.7 | 3.0 | 2.2 | 0.4 | -4.4 | -9.5 |
| EPS ₹ | 0.15 | 0.08 | 0.05 | 0.16 | 0.15 | 0.22 | 0.12 | 0.20 | 0.35 | 0.31 | 0.12 | 0.37 | 0.45 | 0.34 | 0.42 | 0.65 | 1.14 | 0.15 | -1.46 | -4.57 | -3.22 | -1.90 | 0.73 | -4.45 | -0.74 | -0.07 | 2.96 | -0.15 | 1.52 | 0.64 | 2.65 | 2.32 | 2.77 | 2.64 | 3.85 | 3.22 | 3.69 | 3.92 | 4.14 | 2.63 | 4.23 | 3.78 | 1.93 | 0.42 | 1.09 | -2.79 | -3.80 | 0.47 | 0.51 | 1.04 | 3.19 | 5.24 | 7.00 | 4.07 | 1.36 | 2.79 | 2.86 | 2.54 | 4.23 | 1.92 | 1.41 | 0.27 | -2.77 | -6.02 |
| Revenue YoY | — | — | — | — | 4.0% | 28.0% | -3.3% | 20.0% | 9.4% | 12.7% | -2.0% | 13.4% | 17.2% | 14.1% | 23.7% | 12.7% | 17.4% | 9.3% | 24.5% | -31.0% | -47.3% | -6.0% | 13.8% | -24.0% | 38.4% | 7.4% | -17.9% | 109.5% | 54.2% | 65.2% | 99.3% | 80.1% | 66.8% | 30.8% | -6.5% | -3.8% | 5.4% | -2.1% | 24.0% | -10.9% | 8.7% | -8.3% | -23.3% | -1.2% | -13.5% | -34.3% | -28.4% | 10.2% | -6.4% | 27.5% | 83.2% | 59.3% | 44.2% | 43.2% | 3.1% | 1.1% | 17.7% | 5.8% | 33.2% | 4.5% | -5.1% | -32.5% | -24.7% | -20.1% |
| Profit YoY | — | — | — | — | 5.3% | 163.6% | 150.0% | 23.8% | 130.0% | 41.4% | 0.0% | 88.5% | 28.3% | 9.8% | 266.7% | 73.5% | 154.2% | -53.3% | -450.9% | -809.4% | -382.7% | -1290.5% | — | — | — | — | 302.1% | — | — | — | -10.5% | — | 81.6% | 352.4% | 58.7% | 67.2% | 60.0% | 63.2% | 18.4% | -18.4% | 14.7% | -3.5% | -53.4% | -83.9% | -74.2% | -173.9% | -296.4% | 10.4% | -53.2% | — | — | 1020.3% | 1269.1% | 289.7% | -57.4% | -46.7% | -59.2% | -37.5% | 211.2% | -32.1% | -50.8% | -89.3% | -165.6% | -418.0% |
Returns & margins
trailing-twelve-month, per quarter| JUN '24 | SEP '24 | DEC '24 | JUN '26 | SEP '26 | |
|---|---|---|---|---|---|
| ROE | 0.0% | 0.0% | 0.0% | -9.5% | -11.2% |
| ROCE | 7.0% | 9.2% | 9.9% | -12.7% | -13.7% |
| Net margin | 0.0% | 0.0% | 0.0% | -4.2% | -3.8% |
| EBITDA margin | 9.7% | 10.0% | 10.8% | -3.9% | -2.8% |
| Debt / equity | 0.65 | 0.51 | 0.51 | 1.02 | 1.00 |
| Interest coverage | 1.41 | 1.39 | 1.48 | -1.67 | -1.64 |
| Asset turnover | 0.83 | 0.98 | 0.95 | 0.74 | 0.88 |
Balance sheet
equity vs borrowings over time · ₹ crore| SEP '23 | MAR '24 | SEP '24 | SEP '25 | MAR '26 | SEP '26 | |
|---|---|---|---|---|---|---|
| Share capital | 15.8 | 15.8 | 15.8 | 15.8 | 15.8 | 15.8 |
| Other equity / reserves | 116.6 | 120.0 | 132.1 | 111.8 | 87.2 | 72.1 |
| Total equity | 132.4 | 135.8 | 148.0 | 127.6 | 103.1 | 87.9 |
| Borrowings | 75.5 | 88.0 | 74.7 | 89.1 | 105.5 | 88.0 |
| Current liabilities | 209.1 | 163.8 | 192.4 | 168.7 | 196.6 | 198.0 |
| Non-current liabilities | 39.2 | 33.9 | 23.8 | 20.5 | 15.3 | 12.4 |
| Total assets | 380.7 | 333.4 | 364.1 | 316.7 | 315.0 | 298.3 |
| Property, plant & equipment | 105.9 | 104.2 | 108.7 | 114.4 | 115.7 | 110.4 |
| Capital work-in-progress | 0.0 | 0.0 | 0.0 | 3.5 | 0.0 | 0.0 |
| Investments | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Inventories | 140.5 | 123.6 | 142.9 | 116.9 | 102.8 | 96.3 |
| Receivables | 29.0 | 27.9 | 25.6 | 17.0 | 40.3 | 32.9 |
| Cash & equivalents | 5.7 | 0.9 | 6.1 | 3.4 | 0.7 | 0.8 |
Cash flow
annual · ₹ crore · line = free cash flow| FY24 | FY26 | |
|---|---|---|
| Cash from operations | -11.1 | 4.2 |
| Cash from investing | 0.0 | -11.7 |
| Cash from financing | 0.0 | 5.7 |
| Capex | 0.0 | 11.9 |
| Free cash flow | -11.1 | -7.7 |
| Dividends paid | 0.0 | 0.0 |
Where the assets sit
Sep '26 · ₹ croreFixed assets (PPE)₹110.4 cr37%
Inventories₹96.3 cr32%
Receivables₹32.9 cr11%
Cash & equivalents₹0.8 cr0%
Other assets₹57.9 cr19%
Peer comparison
largest in Unclassified · this company in bold| Company | Market cap ₹cr | Price | P/E | P/B | ROE |
|---|---|---|---|---|---|
| Avantel Limited | 36,86,04,549 | 138.69 | — | 1059360.68 | 0.0% |
| Ducol Organics And Colours Limited | 19,55,275 | 120.00 | — | 20089.13 | 0.0% |
| Jio Platforms Limited | 12,57,181 | 1,406.40 | — | 3.57 | — |
| SBI Funds Management Limited | 1,01,750 | 499.55 | — | — | — |
| Tamilnadu Telecommunication Limited | 91,314 | 9.93 | — | — | — |
| Manipal Health Enterprises Limited | 76,294 | 646.70 | — | — | — |
| INDO-MIM Limited | 59,042 | 1,219.50 | — | — | — |
| AvenuesAI Limited | 45,138 | 129.25 | 153.6 | 9.51 | 6.2% |
| Dhoot Transmission Limited | 32,761 | 1,601.60 | — | 8.11 | — |
| 3M India Limited | 31,071 | 27,570.00 | 53.8 | 17.57 | 32.7% |
| Mangalam Drugs And Organics Limited | 46 | 28.80 | — | 0.52 | -11.2% |
StoxGud checklist: Bearish setup · 2/10
- Price above 50-day average
- Price above 200-day average
- 50-day average above 200-day (uptrend)
- RSI in healthy 40–70 zone
- Positive 1-year return
- Return on equity above 15%
- Debt to equity below 1
- Revenue growing year on year
- Net profit margin above 10%
- P/E below industry median
A rules-based screen of trend, momentum, quality and valuation. Educational only — not a buy or sell recommendation.
Returns & technicals
1 month-13.0%
6 months-3.1%
1 year-56.6%
3Y CAGR-34.2%
5Y CAGR-26.5%
10Y CAGR-15.6%
50-day avg₹31.01
200-day avg₹30.75
RSI (14)36
FAQs
What is the share price of Mangalam Drugs And Organics Limited?
Mangalam Drugs And Organics Limited (MANGALAM) closed at ₹28.80 on NSE on 06 Nov 2026.
What is the market cap of Mangalam Drugs And Organics Limited?
₹46 crore at the latest close.
How fast is Mangalam Drugs And Organics Limited growing?
Mangalam Drugs And Organics Limited: Latest-quarter revenue is up 60.3% year on year.
How profitable is Mangalam Drugs And Organics Limited?
On a trailing-twelve-month basis return on equity is -11.2%, return on capital employed -13.7%, operating margin -2.8%, net margin -3.8%.
How much debt does Mangalam Drugs And Organics Limited have?
Mangalam Drugs And Organics Limited is moderately geared: debt to equity is 1.00 with borrowings of ₹88 cr against cash of ₹1 cr (balance sheet of 2026-09-30). Operating profit covers interest -1.6 times.
Financials parsed from Mangalam Drugs And Organics Limited's own XBRL filings to NSE (consolidated), ₹ crore unless marked. Quarterly from SEP '23, annual from FY24, balance sheet from Sep '23. * = derived (full year or half year minus earlier quarters). Information only, not investment advice.
Mangalam Drugs And Organics Limited · advanced chart